In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Opens Up to Europe

Executive Summary

Despite a strong trend among Big Pharma towards in-licensing over the last decade, Merck & Co. hasn't been particularly willing to embrace research ideas outside its own labs. But that's changing. Merck's new European in-licensing initiative proves that the Big Pharma recognizes, and hopes to access, the wealth of science and potential deals beyond US borders.
Advertisement

Related Content

Merck's Deal Focus
The Winners Post-Vioxx: Merck's Product-Focused Biotechs
Merck/DeCode: Just Another Pharmacogenomics Deal?
Merck Deal Gives Lundbeck US Foothold
Eastern Europe: The Local Advantage
KuDOS/Novacea: Pooling Biotech Resources
Merck's Vaccines: Why the Company's Down, but Definitely Not Out
Roche's Partners: Replacing, or Fuelling In-House R&D?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel